Efficiency and Value

The article argues that the United States lacks a strong health technology assessment system comparable to some other wealthy countries. The article argues that FDA approval does not answer whether a drug is best, cost-effective, or accurately represented in journal articles. Health technology assessment independently evaluates drugs, devices, and therapies for comparative medical value and often cost-effectiveness. The project intends to document actual benefits and drawbacks rather than relying on theoretical promises. The qualitative component explains why measured quantitative outcomes occurred and how professionals experience changes. WP3 collects operational, human resource, and financial data from provider information systems and administrative databases. The article criticizes restrictions that prevent U.S. federal guidance from considering comparative costs in recommendations. WP3 examines how the AI system affects efficient and flexible work conditions and what value it creates for healthcare professionals. An independent health technology assessment entity would compare new therapies with existing ones and assess both clinical value and cost-effectiveness.